Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab
JAMA Oncol
.
2021 Feb 1;7(2):309.
doi: 10.1001/jamaoncol.2020.6989.
Authors
Manuel David Gil-Sierra
1
2
,
Marina Sánchez-Hidalgo
1
,
Catalina Alarcón de la Lastra-Romero
1
Affiliations
1
Pharmacy Faculty, Pharmacology Department, University of Sevilla, Sevilla, Spain.
2
Pharmacy Department, Hospital Doctor José Molina Orosa, Arrecife, Spain.
PMID:
33355598
DOI:
10.1001/jamaoncol.2020.6989
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Clinical Decision-Making
Humans
Ipilimumab
Neoadjuvant Therapy*
Nivolumab*
Substances
Ipilimumab
Nivolumab